Skip to main content
RDY
NYSE Life Sciences

Dr. Reddy's Launches First-to-Market Generic Bosulif® (Bosutinib) in US with 180-Day Exclusivity

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.3
Mkt Cap
$11.167B
52W Low
$12.185
52W High
$16.17
52W Position info
9.2% above low
Off High info
18% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

RDY is trading near its 52-week low of $12.185 (9.2% above the low).

Summary

Dr. Reddy's has launched the first generic version of Bosulif® (Bosutinib) in the U.S., securing 180 days of market exclusivity for a drug with over $250 million in annual sales.


Key Events · Product Development and Regulatory · RDY

  • First-to-Market Generic Launch

    Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States.

  • 180-Day Market Exclusivity

    The company achieved "first-to-file" status, granting it 180 days of generic drug exclusivity for this product strength in the U.S.

  • Significant Market Opportunity

    The branded drug, Bosulif® 400mg, recorded approximately $253.8 million in U.S. sales over the last 12 months, representing a substantial revenue opportunity for Dr. Reddy's.

  • Oncology Portfolio Expansion

    This launch expands Dr. Reddy's oncology portfolio, reinforcing its commitment to providing affordable, high-quality medicines in a critical therapeutic area.


Analysis · RDY · Life Sciences

Dr. Reddy's Laboratories has launched the first generic equivalent of Bosulif® (Bosutinib Tablets 400mg) in the United States. This launch is significant because the company secured "first-to-file" status, granting it 180 days of generic drug exclusivity for this strength. The branded drug had U.S. sales of approximately $253.8 million in the past year, indicating a substantial market opportunity for Dr. Reddy's during its exclusivity period. This strategic entry into the oncology market is a positive development, especially following recent reports of profit and revenue declines in North America.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RDY was trading at $13.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.2B. The 52-week trading range was $12.19 to $16.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDY - Latest Insights

RDY
Nov 05, 2026, 6:06 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $14.80 info
Change: +$0.050 (+0.34%) info
Market Cap: $12.332B info
RDY
Nov 03, 2026, 1:09 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $14.38
Real-time Price: $14.80 info
Change: +$0.424 (+3%) info
Market Cap: $12.332B info
RDY
Nov 02, 2026, 12:25 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $14.80 info
Change: +$0.705 (+5%) info
Market Cap: $12.332B info
RDY
Oct 23, 2026, 12:22 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.22
Real-time Price: $14.80 info
Change: +$1.59 (+12%) info
Market Cap: $12.332B info
RDY
Oct 14, 2026, 12:43 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.82
Real-time Price: $14.80 info
Change: +$1.99 (+15%) info
Market Cap: $12.332B info